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Abstract
System L is a major nutrient transport system responsible for the transport of large neutral amino acids including several
essential amino acids. We previously identified a transporter (L-type amino acid transporter 1: LAT1) subserving system L in
C6 rat glioma cells and demonstrated that LAT1 requires 4F2 heavy chain (4F2hc) for its functional expression. Since its
oncofetal expression was suggested in the rat liver, it has been proposed that LAT1 plays a critical role in cell growth and
proliferation. In the present study, we have examined the function of human LAT1 (hLAT1) and its expression in human
tissues and tumor cell lines. When expressed in Xenopus oocytes with human 4F2hc (h4F2hc), hLAT1 transports large
neutral amino acids with high affinity (Km =V15^V50 WM) and L-glutamine and L-asparagine with low affinity
(Km =V1.5^V2 mM). hLAT1 also transports D-amino acids such as D-leucine and D-phenylalanine. In addition, we show
that hLAT1 accepts an amino acid-related anti-cancer agent melphalan. When loaded intracellularly, L-leucine and L-
glutamine but not L-alanine are effluxed by extracellular substrates, confirming that hLAT1 mediates an amino acid
exchange. hLAT1 mRNA is highly expressed in the human fetal liver, bone marrow, placenta, testis and brain. We have
found that, while all the tumor cell lines examined express hLAT1 messages, the expression of h4F2hc is varied particularly in
leukemia cell lines. In Western blot analysis, hLAT1 and h4F2hc have been confirmed to be linked to each other via a
disulfide bond in T24 human bladder carcinoma cells. Finally, in in vitro translation, we show that hLAT1 is not a
glycosylated protein even though an N-glycosylation site has been predicted in its extracellular loop, consistent with the
property of the classical 4F2 light chain. The properties of the hLAT1/h4F2hc complex would support the roles of this
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transporter in providing cells with essential amino acids for cell growth and cellular responses, and in distributing amino
acid-related compounds. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Amino acid transport across the plasma membrane
is mediated via amino acid transporters located on
the plasma membrane. Among the amino acid trans-
port systems described, system L is a major route for
providing cells with large neutral amino acids includ-
ing branched or aromatic amino acids [1]. System L,
a Na-independent neutral amino acid transport
agency, was originally identi¢ed in Ehrlich ascites
carcinoma cells [2]. By expression cloning, we iso-
lated, from C6 rat glioma cells, a cDNA encoding
a Na-independent transporter LAT1 (L-type amino
acid transporter 1), subserving the amino acid trans-
port system L [3]. LAT1 preferentially transports
large neutral amino acids such as leucine, isoleucine,
valine, phenylalanine, tyrosine, tryptophan, methio-
nine and histidine [3]. We and other researchers fur-
ther demonstrated that LAT1 requires an additional
protein, the heavy chain of the 4F2 antigen which
forms a heterodimeric functional complex with the
LAT1 protein [3^6].
The 4F2 antigen (CD98) was originally identi¢ed
as a cell-surface antigen associated with lymphocyte
activation [7,8]. It was later shown to be involved in
various cellular activities such as cell proliferation,
cell transformation and cell adhesion [7^11]. The
4F2 antigen is a heterodimeric complex composed
of two subunits, an V80-kDa glycosylated heavy
chain and a V40-kDa nonglycosylated light chain
[7,8]. The 4F2 heavy chain (4F2hc) is an integral
membrane protein with a single-membrane spanning
domain, classi¢ed as a type II membrane glycopro-
tein [12^14]. Transporters subserving the amino acid
transport systems L, y+L, x3C and asc have been
shown to require 4F2hc for their functional expres-
sion, suggesting that these amino acid transporters
are 4F2 light chains [3^6,15^21]. Furthermore, a pro-
tein structurally related to the 4F2hc-associated
transporters has been determined to couple with
the cystinuria-related type II membrane glycoprotein
rBAT (related to b0; amino acid transporter) and
exhibit a function corresponding to that of system
b0;, thereby establishing a family of amino acid
transporters associated with type II membrane gly-
coproteins (LAT family) [22^24].
In transformed cells, it has been proposed that
amino acid transporters are upregulated to support
the high-level protein synthesis for continuous
growth and proliferation [1]. It was previously re-
ported that TA1/E16, a partial sequence correspond-
ing to LAT1, was strongly expressed in rat trans-
formed cell lines and the rat fetal liver whereas it
was not detected in the adult liver [25]. TA1/E16
immunoreactivity was shown to be strong in human
colon cancer tissues in vivo but barely detected in the
surrounding normal colon tissues [26]. LAT1 expres-
sion has, therefore, been proposed to be related to
the growth and proliferation of tumor cells and cells
during tissue development [3,25,26]. Although the
cDNA for human LAT1 was cloned and analyzed
by transiently expressing it in human retinal pigment
epithelial (HRPE) cells [27], its functional properties
and substrate selectivity were not fully examined. In
the present study, in order to investigate the role of
LAT1 in human tumor cells, we isolated a cDNA
encoding human LAT1 from PA-1 teratocarcinoma
cells. We report here a more extensive characteriza-
tion of its functional properties by expressing it in
Xenopus oocytes and the protein characterization us-
ing antibodies raised against LAT1 and 4F2hc. We
also report the expression of LAT1 and 4F2hc in
human tumors cell lines by Northern blot analysis
using human LAT1 cDNA as a probe.
2. Materials and methods
2.1. Functional characterization
Human LAT1 (hLAT1) cDNA (GenBank/EMBL/
DDBJ accession no. AB018009) was isolated from
the oligo dT-primed cDNA library prepared from
human teratocarcinoma PA-1 cell poly(A) RNA
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(Clontech) using a fragment corresponding to nu-
cleotides 1135^1529 of rat LAT1 cDNA (GenBank/
EMBL/DDBJ accession no. AB015432) as a probe,
as described elsewhere [16,21,28,29]. The amino acid
sequence of hLAT1 was 100% identical to that of the
human LAT1 published by Prasad et al. [27].
For functional expression in Xenopus oocytes,
cRNAs for hLAT1 and human 4F2hc (h4F2hc)
(GenBank/EMBL/DDBJ accession no. AB018010)
were obtained by in vitro transcription using T3
RNA polymerase for hLAT1 in pBluescript II SK3
(Stratagene) linearized with XhoI and T7 RNA poly-
merase for human 4F2hc (h4F2hc) in pZL1 (Life
Technologies Inc.) linearized with BamHI, as de-
scribed elsewhere [30]. Xenopus oocyte expression
studies and uptake measurements were performed
as described previously [28,31] with minor modi¢ca-
tions. Xenopus oocytes were injected with 17.6 ng of
hLAT1 cRNA and 7.4 ng of h4F2hc cRNA at a ¢nal
molar ratio of 1:1. To express solely hLAT1 or
h4F2hc in Xenopus oocytes, 17.6 ng and 7.4 ng of
cRNAs were injected for hLAT1 and h4F2hc, respec-
tively. Two days after injection, the uptake of 14C-
labeled amino acids was measured in the Na-free
uptake solution (100 mM choline-Cl, 2 mM KCl, 1
mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 5 mM
Tris, pH 7.4) containing 0.5^2.0 WCi/ml [14C]amino
acids (DuPont NEN) as described elsewhere [28].
For the Na-containing uptake solution, choline-
Cl in the Na-free uptake solution was replaced with
NaCl. For the Cl3-free uptake solution, Cl3 in the
Na-containing uptake solution was replaced with
gluconate anion. Preliminary experiments to deter-
mine the time-course of L-[14C]leucine (20 WM) up-
take into oocytes expressing hLAT1 indicated that
the uptake was linearly dependent on incubation
time up to 45 min (data not shown); thus, for all
the subsequent experiments, amino acid uptake rate
was measured for 30 min and expressed as pmol/oo-
cyte/min.
Km and Vmax of amino acid substrates were deter-
mined using the Eadie^Hofstee equation based on
the hLAT1-mediated amino acid uptakes measured
at 1, 3, 10, 30, 100 and 300 WM, except for those of
glutamine and asparagine, the uptakes of which were
measured at 0.03, 0.1, 0.3, 1, 3 and 10 mM. To mea-
sure the Ki value of melphalan, the hLAT1-mediated
transport of L-[14C]leucine was measured in the Na-
free uptake solution with varying concentrations of
L-[14C]leucine (3, 5, 10, 30, 100 and 300 WM) with or
without melphalan (100 WM). The Ki values were
determined by double reciprocal plot analysis
[32,33]. The hLAT1-mediated amino acid uptakes
were calculated as the di¡erences between the means
of uptakes of the oocytes injected with hLAT1 and
h4F2hc cRNAs and those of the control oocytes in-
jected with water.
For the e¥ux measurement, 100 nl (2 nCi) of L-
[14C]-labeled amino acids (V400 WM) was injected
into oocytes using a ¢ne-tipped glass micropipette
as described elsewhere [19,21,33]. Oocytes were indi-
vidually incubated for 5 min in the ice-cold Na-free
uptake solution, and transferred to the Na-free up-
take solution with or without 20 WM nonradiolabeled
L-leucine maintained at room temperature (18^22‡C).
The radioactivity of the medium and the residual
radioactivity of the oocytes were measured. The ef-
£ux values were expressed as percent radioactivity
(radioactivity of medium/(radioactivity of medium+-
radioactivity of oocytes)U100%) [19,21,33].
For the uptake and e¥ux measurements, seven to
eight oocytes were used for each data point. Each
data point in the ¢gures represents the mean þ s.e.m.
of uptake (n = 7^8). To con¢rm the reproducibility of
results, three separate experiments using di¡erent
batches of oocytes and in vitro transcribed cRNA
were performed for each measurement except for
Km and Vmax determination (see Table 1). Results
from the representative experiments are shown in
the ¢gures.
2.2. Northern analysis
The SmaI fragment corresponding to 649^1128 bp
of hLAT1 cDNA (GenBank/EMBL/DDBJ accession
no. AB018009) and the PstI fragment corresponding
to 106^645 bp of h4F2hc cDNA (GenBank/EMBL/
DDBJ accession no. AB018010) were labeled with
[32P]dCTP using a T7Quick prime kit (Pharmacia).
Multiple Tissue Northern blots (Human, Human
II, Human immune II: Clontech) were hybridized
with the probes and processed following the manu-
facturer’s instructions. Total RNA was prepared
from human tumor cell lines using an RNA prepa-
ration kit (Isogen, Nippon-Gene, Japan) following
the manufacturer’s instructions. The total RNA (10
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Wg/lane) was separated on a 1% agarose gel in the
presence of 2.2 M formaldehyde and was blotted
onto a nitrocellulose ¢lter (Schleicher and Schuell)
[28,34]. Hybridization was performed for 20 h at
42‡C as described elsewhere [28,34]. The ¢lters were
washed in 0.1USSC/0.1% sodium dodecyl sulfate
(SDS) at 65‡C. Tumor cell lines were provided by
the Health Science Research Resources Bank, Japan
Health Sciences Foundation (Osaka, Japan) and
Riken Cell Bank (Tsukuba, Japan).
2.3. Anti-peptide antibody generation
Oligopeptides [CQKLMQVVPQET] correspond-
ing to amino acid residues 497^507 of hLAT1 and
oligopeptides [EPHEGLLLRFPYAAC] correspond-
ing to amino acid residues 516^529 of h4F2hc were
synthesized. The N-terminal or C-terminal cysteine
residues were introduced for conjugation with key-
hole limpet hemocyanine. Anti-peptide polyclonal
antibodies were generated as described elsewhere
[22,35]. Antisera were a⁄nity-puri¢ed as described
elsewhere [36].
2.4. Western blot analysis
T24 cell membranes were prepared as described
elsewhere [21,22,33,37], with minor modi¢cations.
Brie£y, T24 cells were homogenized in 9 volumes
of a solution containing 50 mM Tris^HCl (pH 7.5),
25 mM KCl, 1 mM MgCl2, 1 mM phenylmethylsul-
fonyl £uoride and 0.25 M sucrose, with 15 strokes in
a Dounce homogenizer. The homogenate was centri-
fuged for 10 min at 8000Ug, and the supernatant
was centrifuged further for 1 h at 100 000Ug. After
centrifugation, the membrane pellet was resuspended
in a solution containing 0.25 M sucrose, 100 mM
KCl, 5 mM MgCl2 and 50 mM Tris (pH 7.4). The
protein samples were heated at 100‡C for 5 min in
the sample bu¡er either in the presence (reducing
condition) or absence (nonreducing condition) of
5% 2-mercaptoethanol and then subjected to SDS^
polyacrylamide gel electrophoresis. The separated
proteins were transferred electrophoretically to a Hy-
bond-P PVDF transfer membrane (Amersham) that
was then treated with nonfat dried milk and an af-
¢nity-puri¢ed anti-hLAT1 antibody (1:500 dilution)
or anti-h4F2hc antiserum (1:20,000 dilution). The
membrane was then treated with horseradish peroxi-
dase-conjugated anti-rabbit IgG as the secondary
antibody (Jackson Immuno Research Laboratories).
The signals were detected using an ECL plus system
(Amersham) [21,22,33].
2.5. In vitro translation
In vitro translation of cRNA for hLAT1 was per-
formed using a rabbit reticulocyte lysate system with
or without a canine pancreatic microsome membrane
(Promega) and endoglycosidase H (Boehringer
Mannheim) as described elsewhere [3,16,38,39].
3. Results
3.1. Transport activities
As shown in Fig. 1A, hLAT1 requires h4F2hc for
its functional expression in Xenopus oocytes. For all
subsequent experiments, therefore, hLAT1 was coex-
pressed with h4F2hc in Xenopus oocytes for func-
tional analyses. The uptake of L-[14C]leucine medi-
ated by hLAT1 was saturable and followed the
Michaelis^Menten kinetics with a Km value of
Table 1
Kinetic parameters of amino acid substrates
Amino acid Km (WM)a Vamax
L-Leucine 19.7b (1.00)
L-Isoleucine 25.1 1.18
L-Phenylalanine 14.2 0.91
L-Methionine 20.2 1.28
L-Tyrosine 28.3 0.86
L-Histidine 12.7 0.80
L-Tryptophan 21.4 0.65
L-Valine 47.2 1.35
L-Glutamine 1,640 1.61
L-Asparagine 2,150 0.73
D-Leucine 74.8 1.11
D-Phenylalanine 121 1.32
aKm and Vmax values were determined as described in Section
2. The data were obtained from six separate experiments using
di¡erent batches of oocytes. In each experiment, L-leucine up-
take was measured to compare Vmax values between experi-
ments. The Vmax value of each amino acid was normalized to
that of L-leucine in the same experiment.
bKm for L-leucine is the mean of four measurements (mean þ
S.E.M. = 19.7 þ 4.1 WM).
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19.7 þ 4.1 WM (mean þ s.e.m. of four separate experi-
ments) (Fig. 1B). The L-[14C]leucine uptake was not
dependent on Na or Cl3 (data not shown).
3.2. Substrate selectivity
The substrate selectivity of hLAT1 was investi-
gated in the inhibition experiments in which 20 WM
L-[14C]leucine uptake was measured in the presence
of an amino acid at 2 mM. The L-leucine uptake was
strongly inhibited by L-isomers of isoleucine, phenyl-
alanine, methionine, tyrosine, histidine, tryptophan,
valine and a conventional system L-speci¢c inhibitor,
namely, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic
acid (BCH) (Fig. 2A). All the natural amino acids
were con¢rmed to be transported by hLAT1 using
radiolabeled compounds (Fig. 2C). The Km values
for these substrate amino acids were between V15
and V50 WM, indicating a high-a⁄nity transport
(Table 1). Basic amino acids, such as lysine and ar-
ginine, and acidic amino acids, such as glutamate
and aspartate, did not inhibit L-[14C]leucine uptake
(Fig. 2A). D-Isomers of leucine, phenylalanine and
methionine strongly inhibited the hLAT1-mediated
L-[14C]leucine uptake, whereas hLAT1 was highly
stereoselective for tyrosine, histidine, tryptophan, va-
line and isoleucine (Fig. 2B). Using radiolabeled
compounds, D-leucine and D-phenylalanine were
shown to be transported with high a⁄nity by
hLAT1 (Fig. 2C and Table 1). Although the level
of inhibition of L-[14C]leucine uptake by glutamine
and asparagine was low, they were in fact trans-
ported with low a⁄nity (Table 1).
3.3. Interaction of amino acid-related compounds with
hLAT1
The hLAT1-mediated L-[14C]leucine uptake (1
WM) was measured in the presence of 100 WM non-
labeled L-Dopa, triiodothyronine, thyroxine and mel-
phalan. As shown in Fig. 3A, L-[14C]leucine uptake
was markedly inhibited by these amino acid-related
compounds. Triiodothyronine exerted the strongest
inhibition of hLAT1-mediated L-[14C]leucine uptake
(Fig. 3A). As shown in Fig. 3B, the inhibition of L-
[14C]leucine uptake by melphalan was shown to be
competitive in a double reciprocal plot analysis with
a Ki value of 56 WM.
3.4. Amino acid exchange mediated by hLAT1
As shown in Fig. 4, L-leucine applied extracellu-
larly induced the e¥ux of a preloaded high-a⁄nity
substrate L-[14C]leucine and a low-a⁄nity substrate
L-[14C]glutamine but not a nonsubstrate L-
[14C]alanine from the oocytes expressing hLAT1. L-
Fig. 1. Functional expression of hLAT1 in Xenopus oocytes.
(A) Coexpression of hLAT1 and h4F2hc. The uptake of L-
[14C]leucine (50 WM) by Xenopus oocytes injected with water,
hLAT1 cRNA (labeled as ‘hLAT1’), 4F2hc cRNA (‘4F2hc’),
and both hLAT1 cRNA and 4F2hc cRNA (‘hLAT1+4F2hc’)
was measured in the Na-free uptake solution. The coexpres-
sion of hLAT1 and 4F2hc resulted in a high uptake of L-
[14C]leucine. (B) Concentration dependence of hLAT1-mediated
L-[14C]leucine uptake. The hLAT1-mediated L-[14C]leucine up-
take in oocytes coexpressing hLAT1 and h4F2hc was measured
at 1, 3, 10, 30, 100, and 300 WM L-leucine in the Na-free up-
take solution, and plotted against L-leucine concentration. The
uptake was saturable and ¢t the Michaelis^Menten curve. Inset:
Eadie^Hofstee plot of the L-leucine uptake from which kinetic
parameters were determined.
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Fig. 2. Substrate selectivity of hLAT1. (A) Inhibition of hLAT1-mediated L-[14C]leucine uptake by glycine, L-amino acids and BCH.
The hLAT1-mediated L-[14C]leucine uptake (20 WM) was measured in the presence of 2 mM nonradiolabeled glycine, L-amino acids
and system L-speci¢c inhibitor BCH, and expressed as percent of the control L-[14C]leucine uptake in the absence of inhibitors (‘(3)’).
The L-leucine uptake was highly inhibited by BCH and neutral amino acids with branched or aromatic side chains. BCH, 2-aminobi-
cyclo-(2,2,1)-heptane-2-carboxylic acid. (B) Inhibition of LAT1-mediated L-[14C]leucine uptake by D-amino acids. The LAT1-mediated
L-[14C]leucine uptake (20 WM) was measured in the presence of 2 mM nonradiolabeled D-amino acids and expressed as percent of the
control L-[14C]leucine uptake in the absence of inhibitors (‘(3)’). D-Leucine, D-phenylalanine and D-methionine strongly inhibited
hLAT1-mediated L-[14C]leucine uptake. (C) hLAT1-mediated uptakes of 20 WM L-[14C]- and D-amino acids were measured. hLAT1
transported neutral L-amino acids with branched or aromatic side chains. hLAT1 also transported D-leucine and D-phenylalanine.
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leucine did not induce the e¥ux of preloaded 14C-
labeled amino acids from the control oocytes, con-
¢rming that the amino acid e¥ux was mediated by
hLAT1 (Fig. 4).
3.5. Tissue distribution and expression in tumor cell
lines
The distribution of hLAT1 and h4F2hc mRNAs in
human tissues was analyzed by Northern blot anal-
ysis. A single mRNA band of 4.8 kb was detected in
samples of brain, placenta, testis, peripheral blood
leukocytes, bone marrow, fetal liver, lymph node
and thymus (Fig. 5A). The blots from the analysis
were also hybridized with a 32P-labeled h4F2hc
probe. The h4F2hc signal was detected ubiquitously.
The placenta, kidney and testis showed a relatively
higher expression level of 4F2hc mRNA (Fig. 5B).
The hLAT1 and h4F2hc mRNAs were detected in
the human carcinoma cell lines such as PA-1 terato-
carcinoma cells, T24 bladder carcinoma cells, RERF-
LC-MA lung small-cell carcinoma cells and HeLa
uterine cervical carcinoma cells (Fig. 6A). In human
leukemia cell lines, hLAT1 was expressed in all the
cell lines examined, whereas the expression level of
h4F2hc varied among the cell lines (Fig. 6B). The
h4F2hc signal was not detected in Daudi Burkitt
lymphoma cells, CCRF-SB acute lymphoblastic leu-
kemia (B-lymphoblastoid leukemia) cells and P30/
OHK non-T non-B acute lymphoblastic leukemia
cells by Northern blot analysis (Fig. 6B).
3.6. Association of hLAT1 and h4F2hc in T24 cells
Western blot analysis was performed on the mem-
brane fractions prepared from T24 human bladder
carcinoma cells. The antibodies raised against
hLAT1 (Fig. 7, left) and h4F2hc (Fig. 7, right)
both recognized the 125-kDa-protein band under
Fig. 3. Interaction of hLAT1 with amino acid-related drugs.
(A) The hLAT1-mediated L-[14C]leucine uptake (1 WM) was
measured in the presence of 100 WM nonradiolabeled com-
pounds, and expressed as percent of the control L-[14C]leucine
uptake in the absence of inhibitors (‘(3)’). The uptakes in the
presence of 0.1% dimethyl sulfoxide were measured. T3, triiodo-
thyronine; T4, thyroxine. (B) Inhibitory e¡ect of melphalan on
hLAT1-mediated L-[14C]leucine uptake. The hLAT1-mediated
uptake of L-[14C]leucine (3, 5, 10, 30, 100 and 300 WM) was
measured in the Na-free uptake solution in the presence (b)
or absence (a) of 100 WM melphalan. Double reciprocal plot
analyses were performed. The Ki value of melphalan was calcu-
lated to be 56 WM.
Fig. 4. E¥ux of intracellularly injected [14C]amino acids via
hLAT1. Oocytes coexpressing hLAT1 and h4F2hc (labeled as
‘hLAT1+h4F2hc’) or control oocytes injected with water in-
stead of cRNAs (‘Control’) were preloaded with 14C-labeled L-
leucine, L-glutamine and L-alanine by microinjection (V400 WM
[14C]amino acids; 100 nl (2 nCi)/oocyte). E¥ux of the pre-
loaded radioactivity in the presence (closed column) or absence
(open column) of 20 WM of L-leucine in the Na-free uptake
solution was measured. The values are expressed as a percent
of the total radioactivity microinjected into the oocytes.
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the nonreducing condition, whereas this band shifted
to the 38-kDa-protein band for hLAT1 (Fig. 7, left)
and 85-kDa-protein band for h4F2hc under the re-
ducing condition (Fig. 7, right).
3.7. In vitro translation of hLAT1 cRNA
In vitro translation of hLAT1 cRNA showed a
band of a 42-kDa protein (Fig. 8). hLAT1 was not
glycosylated by canine pancreatic microsomes under
the condition in which 4F2hc is glycosylated [3] (Fig.
8).
4. Discussion
It was previously reported that rat, mouse, Xeno-
pus and human LAT1s are associated with 4F2hc
[3,4,6,27]. We con¢rmed this for hLAT1 by showing
that hLAT1 requires h4F2hc for its functional ex-
pression in Xenopus oocytes (Fig. 1A). When coex-
Fig. 5. Tissue distribution of expression. High-stringency North-
ern blot analysis of poly(A) RNA from human tissues using
probes for hLAT1 (A) and h4F2hc (B). For hLAT1, strong hy-
bridization signals were detected in the brain, placenta, testis,
bone marrow and fetal liver. Weak signals were detected in pe-
ripheral leukocytes, lymph node and thymus (A). Although the
expression of h4F2hc was basically ubiquitous, a higher level of
expression was detected in the placenta, kidney and testis (B).
Fig. 6. Expression of hLAT1 and h4F2hc in human tumor cell
lines. (A) High-stringency Northern blot analysis of total RNA
from human carcinoma cells (PA-1 teratocarcinoma cells, T24
bladder carcinoma cells, RERF-LC-MA lung small-cell carcino-
ma cells, and HeLa uterine cervical carcinoma cells) using
probes for hLAT1 (left) and h4F2hc (right). Strong hybridiza-
tion signals were detected both for hLAT1 and h4F2hc. (B)
High-stringency Northern blot analysis of total RNA from hu-
man leukemia cells using probes for hLAT1 (upper) and
h4F2hc (lower). HeLa cell RNA was included to compare the
expression levels with those shown in A. HL-60, acute promye-
locytic leukemia cells ; KG-1, acute myeloblastic leukemia cells ;
U937, di¡use histiocytic lymphoma cells ; K562, chronic mye-
logenous leukemia (blast crisis) cells ; KU812, chronic myeloid
leukemia cells ; MOLT-3, acute lymphoblastic leukemia cells ;
MOLT-4, acute lymphoblastic leukemia cells ; CCRF-CEM,
acute lymphoblastic leukemia cells ; Jurkat, T-lymphocyte-like
cells ; Daudi, Burkitt lymphoma cells ; CCRF-SB, acute lympho-
blastic leukemia (B-lymphoblastoid leukemia) cells ; P30/OHK,
non-T non-B acute lymphoblastic leukemia cells.
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pressed with h4F2hc, hLAT1 exhibited BCH-sensi-
tive Na-independent high-a⁄nity transport of large
neutral amino acids (Table 1), in agreement with the
properties of system L and already reported proper-
ties of rat, mouse, Xenopus and human LAT1s [1^
4,6,15,27]. In rat LAT1, we previously showed that
D-isomers of leucine, phenylalanine and methionine
strongly inhibited L-[14C]leucine uptake [3]. The
hLAT1-mediated transport was also inhibited by D-
leucine, D-phenylalanine and D-methionine (Fig. 2B).
In the present study, using 14C-labeled D-leucine and
D-phenylalanine, we demonstrated that these D-ami-
no acids are in fact transported by hLAT1 with high
a⁄nity (Fig. 2C and Table 1). The absence of
marked stereoselectivity seems to be a common char-
acteristic of members of the LAT family. For exam-
ple, amino acid transport mediated by LAT2 is also
inhibited by D-isomers of some amino acids such as
serine, cysteine and asparagine, although they are
not transported by LAT2 [16]. Asc-1, which prefers
small neutral amino acids, transports not only L-ami-
no acids but also D-amino acids such as D-serine, D-
alanine, D-threonine and D-cysteine [21,40]. It was
shown that D-amino acids are endogenously present
in mammalian tissues [41]. Thus, LAT1, as well as
Asc-1, is proposed to play signi¢cant roles in the
mobilization of D-amino acids in mammals.
It has been proposed that system L mediates the
transport of amino acid-related compounds [1,42^
44]. As shown in Fig. 3A, the hLAT1-mediated L-
leucine uptake was inhibited by L-Dopa, triiodothyr-
onine, thyroxine and melphalan. These amino acid-
related compounds are proposed to be accepted by
the binding site of hLAT1 and transported by
hLAT1. In agreement with this, it has been shown
that triiodothyronine and thyroxine were transported
by Xenopus LAT1 (ASUR4) [43]. The anticancer
agent melphalan was shown to be transported by
system L in in vivo preparation [44]. The level of
system L activity in tumor cells was reported to be
correlated with melphalan sensitivity [45,46]. In the
present study, we demonstrated that melphalan in-
hibited the hLAT1-mediated L-[14C]leucine uptake
in a competitive manner with a Ki value close to
the Km values of substrate amino acids, indicating
that the binding site of hLAT1 accepts melphalan
with an a⁄nity similar to that of substrate amino
acids (Fig. 3B). Because hLAT1 is upregulated in
tumor cells, it is proposed as one of the major routes
through which melphalan permeates the plasma
membrane to enter tumor cells.
Fig. 7. Association between hLAT1 and h4F2hc proteins. West-
ern blot analysis was performed on the membrane fraction pre-
pared from human bladder carcinoma cell line T24 in the pres-
ence or absence of 2-mercaptoethanol using an anti-hLAT1
antibody and an anti-h4F2hc antibody. For LAT1 (left), the
125-kDa-protein band detected in the absence of 2-mercaptoeth-
anol (‘2ME 3’) was not detected in the presence 2-mercapto-
ethanol (‘2ME +’), and a 38-kDa-protein band was detected in-
stead. For 4F2hc (right), the 125-kDa-protein band detected in
the absence of 2-mercaptoethanol (‘2ME 3’) shifted to an 85-
kDa-protein band by the treatment of 2-mercaptoethanol
(‘2ME +’).
Fig. 8. In vitro translation of hLAT1 cRNA. The autoradio-
graph of SDS^polyacrylamide gel (10%) used to analyze the in
vitro translation products obtained in the absence of pancreatic
microsomes (¢rst lane) and in the presence of microsomes (sec-
ond lane) is shown. The third lane shows the products in the
presence of microsomes after deglycosylation with endoglycosi-
dase H. The fourth lane shows the reaction in the absence of
hLAT1 cRNA, indicating that the upper V50-kDa-protein
band is not produced due to the translation of hLAT1 cRNA.
Translation of hLAT1 cRNA in the absence of microsomes
thus yielded translation products apparently of Mr 42 000. The
hLAT1 translation product was not glycosylated by pancreatic
microsomes.
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For rat LAT1, we previously showed that the ef-
£ux of L-[14C]leucine preloaded into oocytes by in-
cubating them in the L-[14C]leucine-containing me-
dium was induced by adding L-leucine to the
medium, suggesting that rat LAT1 mediated the ami-
no acid exchange [3]. In the present study, we further
examined this by microinjecting 14C-labeled amino
acids into oocytes expressing hLAT1. We showed
that a high-a⁄nity substrate L-leucine and a low-af-
¢nity substrate L-glutamine but not a nonsubstrate L-
alanine were e¥uxed via hLAT1 by the application
of L-leucine in the medium, con¢rming that hLAT1
is an amino acid exchanger (Fig. 4). This, further-
more, suggests that the substrate selectivity of the
intracellular substrate binding site of hLAT1 is sim-
ilar to that of the extracellular substrate binding site.
Northern blot analysis indicated that hLAT1 is
heterogeneously expressed in human tissues with a
high expression in the placenta, testis, bone marrow
and brain, whereas the expression of h4F2hc is
rather ubiquitous (Fig. 5A,B), consistent with the
reports for mice and rats [3,6,16,47,48]. Interestingly,
the fetal liver has a high expression level of the
hLAT1 message whereas this expression was not de-
tected in the adult liver (Fig. 5A), which is in agree-
ment with the observation in rats using a cDNA
probe for TA1/E16, a partial sequence corresponding
to LAT1 [25]. TA1 (rat) was originally identi¢ed as a
tumor-associated sequence with an oncofetal pattern
of expression in the rat liver [25]. TA1 immunoreac-
tivity was found to be strong in human colon cancer
[26], suggesting that hLAT1 is upregulated in human
cancer tissues. In the present study, we examined the
expression of hLAT1 messages in human tumor cell
lines using a hLAT1 cDNA probe. hLAT1 messages
were detected in all the carcinoma and leukemia cell
lines examined, consistent with previous results of
the Northern blot analysis using rat LAT1 cDNA
probes [3,25] (Fig. 6A,B).
An interesting ¢nding of the Northern blot analy-
sis of the tumor cell line is that the expression level of
h4F2hc is quite varied among tumor cell lines partic-
ularly in leukemia cell lines (Fig. 6A,B). We found
three leukemia cell lines in which h4F2hc messages
were not detected (Fig. 6B). In these cell lines that
lack h4F2hc expression, hLAT1 was still expressed,
suggesting di¡erent mechanisms of regulation in
hLAT1 and h4F2hc gene expression. Consistent
with this, it was shown that LAT1 and 4F2hc re-
spond di¡erently to amino acid availability in rat
hepatic cells [49]. It was previously reported that
the level of h4F2hc expression in leukemia cells is
varied among leukemia patients even with the same
clinical diagnosis [50,51]. Because h4F2hc is essential
for hLAT1 to be functional, the level of h4F2hc ex-
pression would greatly a¡ect the formation of func-
tional system L transporters in the plasma membrane
[3,4,52]. It would be interesting to determine how the
h4F2hc expression level in£uences the rate of amino
acid uptakes and eventually a¡ects the growth and
proliferation of tumor cells. The leukemia cell lines
examined in the present study will be useful tools for
investigating this issue.
In previous immunoprecipitation studies, LAT1
(or 4F2 light chain) was coprecipitated with 4F2hc
using anti-4F2hc antibodies under the nonreducing
condition [4^6]. LAT1 and 4F2hc dissociated under
the reducing condition, indicating that LAT1 and
4F2hc are linked via disul¢de bonds. As for
ASUR4 (Xenopus laevis LAT1), a site-directed muta-
genesis study revealed that Cys 164, which is con-
served in di¡erent species, is responsible for the link-
ing with 4F2hc [52]. These studies were performed by
exogenously expressing LAT1 and 4F2hc in Xenopus
oocytes. In order to examine whether hLAT1 and
h4F2hc, which are endogenous to human cells, exist
as a heterodimeric complex in the plasma membrane,
we generated antibodies against hLAT1 and h4F2hc.
We performed Western blot analysis on the mem-
brane fractions prepared from T24 human bladder
carcinoma cells, because T24 cells expressed both
hLAT1 and h4F2hc at high levels (Fig. 6A). We
showed that the 125-kDa-protein band correspond-
ing to the heterodimeric complex of hLAT1 and
h4F2hc detected under the nonreducing condition
shifted to the 38-kDa- and 85-kDa protein bands
corresponding to the hLAT1 and h4F2hc monomers,
respectively, under the reducing condition (Fig. 7).
This indicates that hLAT1 and h4F2hc proteins co-
exist as a heterodimeric complex linked via disul¢de
bonds in T24 cells. This is, in fact, the ¢rst demon-
stration of the band shift using an anti-LAT1 anti-
body. The role of 4F2hc in the functional expression
of LAT1 has been proposed to assist the LAT1 pro-
tein to be sorted to the plasma membrane [4]. Be-
cause hLAT1 is linked to h4F2hc in T24 cells (Fig.
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5), both proteins are expected to be localized in the
plasma membrane. We con¢rmed that hLAT1 and
h4F2hc immunoreactivity coexist on the plasma
membrane of T24 cells by confocal immuno£uores-
cence microscopic analysis [53] (data not shown).
Although the 4F2 light chain has been assumed to
be a nonglycosylated protein [7,8], an N-glycosyla-
tion site is predicted in the putative extracellular
loop of hLAT1, which is not conserved in rat
LAT1 [27]. In rat LAT1, we previously showed
that the LAT1 protein is not glycosylated in in vitro
translation [3]. We, thus, examined, in in vitro trans-
lation, whether hLAT1 is glycosylated or not. The
results indicated that hLAT1 is not glycosylated
under the condition in which 4F2hc is glycosylated
[3] (Fig. 8). Thus, it is con¢rmed that hLAT1 is a
4F2 light chain, i.e., a nonglycosylated subunit of the
4F2 antigen.
Regarding the regulation of the expression of
hLAT1, there are some interesting ¢ndings. E16, a
human partial sequence corresponding to hLAT1,
was reported to be upregulated upon mitogenic stim-
ulation of lymphocytes [54]. ASUR4, the Xenopus
homolog of hLAT1 was identi¢ed to be upregulated
upon stimulation of the A6 epithelial cell line by al-
dosterone [55]. Based on this highly regulated nature,
together with its high levels of expression in tumor
cells, fetal liver and bone marrow, it is speculated
that hLAT1 expression is upregulated in order to
provide cells with essential amino acids for high lev-
els of protein synthesis associated with cell activation
or hormonal stimulation and also to support rapid
growth or continuous proliferation. In order for
hLAT1 to ful¢ll these tasks, it appears a disadvant-
age for hLAT1 to be an amino acid exchanger. Ami-
no acids are released via hLAT1 in exchange for the
in£ux of amino acids, thus no net amino acid in£ux
should be observed. We showed that L-glutamine,
which is abundantly present in cells and generated
intracellularly, is transported by hLAT1 albeit with
low a⁄nity (Table 1), consistent with a previous re-
port for Xenopus LAT1 [4]. We further demonstrated
that intracellularly loaded L-glutamine is e¥uxed in
exchange for extracellularly applied L-leucine. There-
fore, we propose that extracellular high-a⁄nity
LAT1 substrates, most of which are essential amino
acids, are taken up by cells via hLAT1 driven by the
exchange for intracellular L-glutamine, which results
in the net in£ux of essential amino acids.
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